References
LH Silver (1998) ArticleTitleThe Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension Am J Ophthalmol 126 400–408 Occurrence Handle10.1016/S0002-9394(98)00095-6 Occurrence Handle1:CAS:528:DyaK1MXkvFCru7c%3D Occurrence Handle9744373
K Sall (2000) ArticleTitleThe Brinzolamide Primary Therapy Study Group. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension Surv Ophthalmol 44 IssueIDSuppl 2 S155–S162 Occurrence Handle10665518
H Kobayashi K Kobayashi S Okinami (2004) ArticleTitleHypotensive effect and subjective symptoms after substitution of 1% dorzolamide by 1% brinzolamide Rinsho Ganka (Jpn J Clin Ophthalmol) 58 205–209
M Kubota T Hara S Kubota T Hashimoto T Tsuru (2004) ArticleTitleOcular hypotensive effect of brinzolamide after switching from dorzolamide Rinsho Ganka (Jpn J Clin Ophthalmol) 58 301–303
H Barnebey Kwok SY. Patients&apos (2000) ArticleTitleacceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting Clin Ther 22 1204–1212 Occurrence Handle10.1016/S0149-2918(00)83063-5 Occurrence Handle1:CAS:528:DC%2BD3cXosFygtrc%3D Occurrence Handle11110231
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Inoue, K., Wada, Sa., Wakakura, M. et al. Switching from Dorzolamide to Brinzolamide: Effect on Intraocular Pressure and Patient Comfort. Jpn J Ophthalmol 50, 68–69 (2006). https://doi.org/10.1007/s10384-005-0271-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10384-005-0271-3